Dermatomyositis Completed Phase 2 Trials for Rituximab (DB00073)

Also known as: Dermatomyositides / Dermatopolymyositis, unspecified

IndicationStatusPhase
DBCOND0002234 (Dermatomyositis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00106184Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)Treatment